10.11.2016 | Erratum
Erratum to: Dose–response efficacy and safety of PA21 in Japanese hemodialysis patients with hyperphosphatemia: a randomized, placebo-controlled, double-blind, Phase II study
Erschienen in: Clinical and Experimental Nephrology | Ausgabe 3/2017
Einloggen, um Zugang zu erhalten